Developer docs
API playgroundTry for free, no card

Search company profiles

Proton Intelligence

Full company profile

uuid0000w4k

Namestring
Proton Intelligence
Legal namestring
Proton Intelligence Inc.
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Proton Intelligence is a Vancouver-based, privately held medtech company founded in 2020 that is developing the Continuous Potassium Monitoring (CKM) platform — a real-time, on-demand potassium monitoring wearable positioned as the first device of its kind capable of giving clinicians continuous K+ readings for patients at risk of hyperkalemia. The company's core technical proposition is a novel biosensor architecture that enables wearable, continuous measurement of blood potassium, addressing a clinical gap in which no on-demand K+ monitoring capability currently exists to guide hyperkalemia treatment. The company is co-founded by Sahan Ranamukha, PhD (CEO), a biomedical engineer, and Victor Cadarso, PhD (CSO), a physicist and biosensing expert, and is registered as Proton Intelligence Inc. in British Columbia, Canada.

The CKM platform targets two principal end-user segments: clinicians and healthcare providers managing patients with Chronic Kidney Disease (the primary cause of hyperkalemia, affecting 33% of adults over 65 and 3.7M+ Americans), and clinicians treating heart failure patients where hyperkalemia carries cardiac-arrest risk. The product is explicitly labeled an "investigational device," indicating the company is pre-commercial and pursuing regulatory clearance before broad market launch. The intended business model is hardware sales to enterprise healthcare buyers (hospitals, clinical facilities, and nephrology practices), with future potential expansion into at-home use cases for chronic-condition management.

Proton Intelligence is venture-backed at the seed stage, having closed a $6.95M financing round in December 2024 led by SOSV with participation from 15th Rock, Exor, LongeVC, Tenmile, Trampoline Venture Partners, and We Venture Capital. The company has built credibility through selection into multiple medtech and life-sciences accelerators, including IndieBio San Francisco Batch 12 (2022), MedTech Innovator's 2023 Accelerator, Creative Destruction Lab's Vancouver Health Stream, BoostVC's Tribe 18, and e@UBC's Hatch Venture Builder Program. Headcount is reported in the 11-50 range, consistent with an early-stage clinical-development team, and the company currently operates from a single Vancouver headquarters with no disclosed subsidiary structure or international footprint.

Short descriptiontext

Proton Intelligence develops a Continuous Potassium Monitoring (CKM) wearable — the first real-time, on-demand potassium biosensor — to help clinicians manage hyperkalemia in patients with Chronic Kidney Disease and heart failure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersVancouver, Canada
HQ citystring
Vancouver
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
continuous biomarker monitoring, potassium monitoring wearable, chronic kidney disease care, hyperkalemia management, medical wearable devices
Industry2 codes
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
SECONDARYHLAHAKAK
Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Continuous Potassium Monitoring Wearables
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Continuous Potassium Monitoring Device
TypeHardware Sales
Description

Medical device generating revenue through wearable hardware sales to healthcare systems and clinical facilities for continuous potassium monitoring in at-risk patients

protonintelligence.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Proton Intelligence is developing a Continuous Potassium Monitoring (CKM) Platform — a real-time, on-demand potassium monitoring wearable designed to help clinicians treat and manage patients with kidney disease and cardio-kidney-metabolic conditions. The device delivers continuous potassium level data to enable safer, more precise management of hyperkalemia and unlocks life-saving treatments that cannot currently be deployed when patients have dangerous K+ levels.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 3.7M+ Americans affected by hyperkalemia represent the addressable market for potassium monitoring technology
Product overview1 text field

Proton Intelligence offers a single unified product — the Continuous Potassium Monitoring (CKM) Platform — which is a real-time, on-demand potassium monitoring wearable device. This platform is designed to enable clinicians to safely and precisely treat and manage patients with hyperkalemia and chronic kidney disease, unlocking life-saving treatments that cannot be deployed when patients have dangerous potassium levels.

Product and service1 record
1Continuous Potassium Monitoring (CKM) Platform
CategoryContinuous Potassium Monitoring Wearables
Description

A real-time, on-demand potassium monitoring wearable designed to help clinicians treat and manage patients with kidney disease, hyperkalemia, and cardio-kidney-metabolic conditions by providing continuous potassium level data.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-01
Description

Member of MedTech Innovator's 2023 Accelerator program, providing mentorship, resources, and networking for early-stage medical technology companies developing innovative healthcare solutions.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-01-01
Description

Selected for IndieBio's San Francisco Batch 12 accelerator program, a prominent life sciences accelerator providing funding and support for biotech and medtech startups. Featured in TechCrunch coverage of the cohort.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Member of BoostVC's Tribe 18 accelerator program, supporting early-stage companies in the healthcare and blockchain sectors.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Participant in Creative Destruction Lab's Vancouver Health Stream, an accelerator program focused on scalable, seed-stage ventures with high-impact potential in health technology.

5e@UBC Hatch Venture Builder Program
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Participant in e@UBC's Hatch Venture Builder Program, supporting entrepreneurship at the University of British Columbia and providing resources for early-stage venture development.

protonintelligence.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Continuous glucose monitoring wearable leader. Directly comparable as a wearable continuous biomarker monitoring platform with recurring consumables revenue; serves as the most direct analogue for what Proton aims to build in potassium.

TypeDirect peer
Description

CGM platform competing with Dexcom. Comparable wearable continuous biomarker business model and enterprise/payer commercialization playbook relevant to a future CKM go-to-market.

TypeBroad incumbent
Description

Broader medtech incumbent with diabetes and cardiac monitoring franchises. Relevant as a potential strategic acquirer and as a benchmark for an integrated patient-monitoring commercial machine.

TypeDirect peer
Description

Continuous urine output monitoring for critically ill and acute kidney injury patients. Closest direct functional analogue in renal continuous monitoring, addressing similar hospital workflows.

TypeBroad incumbent
Description

Tablo hemodialysis system for kidney care. Comparable as a renal-care device company commercializing novel technology into nephrology workflows; relevant for sales-cycle and reimbursement lessons.

TypeEmerging player
Description

Manufacturer of electrolyte and blood-gas analyzers (including potassium measurement). Comparable as a potassium-measurement technology competitor in clinical settings, though primarily bench-top rather than wearable.

TypeBroad incumbent
Description

Major diagnostic instrument maker including blood-gas/electrolyte analyzers used in clinical potassium measurement. Relevant as a benchmark for incumbent diagnostic adoption and a potential strategic acquirer.

TypeEmerging player
Description

Compact hemodialysis system developer. Comparable as a venture-backed medtech commercializing innovative renal-care technology into clinical workflows with similar reimbursement and adoption dynamics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Proton Intelligence

Continuous Potassium Monitoring Wearablesprotonintelligence.com

Proton Intelligence develops a Continuous Potassium Monitoring (CKM) wearable — the first real-time, on-demand potassium biosensor — to help clinicians manage hyperkalemia in patients with Chronic Kidney Disease and heart failure.

What Proton Intelligence does

Proton Intelligence is a Vancouver-based, privately held medtech company founded in 2020 that is developing the Continuous Potassium Monitoring (CKM) platform — a real-time, on-demand potassium monitoring wearable positioned as the first device of its kind capable of giving clinicians continuous K+ readings for patients at risk of hyperkalemia. The company's core technical proposition is a novel biosensor architecture that enables wearable, continuous measurement of blood potassium, addressing a clinical gap in which no on-demand K+ monitoring capability currently exists to guide hyperkalemia treatment. The company is co-founded by Sahan Ranamukha, PhD (CEO), a biomedical engineer, and Victor Cadarso, PhD (CSO), a physicist and biosensing expert, and is registered as Proton Intelligence Inc. in British Columbia, Canada.

The CKM platform targets two principal end-user segments: clinicians and healthcare providers managing patients with Chronic Kidney Disease (the primary cause of hyperkalemia, affecting 33% of adults over 65 and 3.7M+ Americans), and clinicians treating heart failure patients where hyperkalemia carries cardiac-arrest risk. The product is explicitly labeled an "investigational device," indicating the company is pre-commercial and pursuing regulatory clearance before broad market launch. The intended business model is hardware sales to enterprise healthcare buyers (hospitals, clinical facilities, and nephrology practices), with future potential expansion into at-home use cases for chronic-condition management.

Proton Intelligence is venture-backed at the seed stage, having closed a $6.95M financing round in December 2024 led by SOSV with participation from 15th Rock, Exor, LongeVC, Tenmile, Trampoline Venture Partners, and We Venture Capital. The company has built credibility through selection into multiple medtech and life-sciences accelerators, including IndieBio San Francisco Batch 12 (2022), MedTech Innovator's 2023 Accelerator, Creative Destruction Lab's Vancouver Health Stream, BoostVC's Tribe 18, and e@UBC's Hatch Venture Builder Program. Headcount is reported in the 11-50 range, consistent with an early-stage clinical-development team, and the company currently operates from a single Vancouver headquarters with no disclosed subsidiary structure or international footprint.

Proton Intelligence firmographics

Firmographics
Name
Proton Intelligence
Legal name
Proton Intelligence Inc.
Website
https://protonintelligence.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Short description
Proton Intelligence develops a Continuous Potassium Monitoring (CKM) wearable — the first real-time, on-demand potassium biosensor — to help clinicians manage hyperkalemia in patients with Chronic Kidney Disease and heart failure.
Ownership category
akta.pro rank

Proton Intelligence industry classification

Industry
Product category
Continuous Potassium Monitoring Wearables
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAKAJ
Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status)
SECONDARYHLAHAKAK
Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring)

Keywords

  • Continuous biomarker monitoring
  • Potassium monitoring wearable
  • Chronic kidney disease care
  • Hyperkalemia management
  • Medical wearable devices

Where Proton Intelligence is headquartered

Location

Headquarters

HQ city
Vancouver
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Proton Intelligence business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Continuous Potassium Monitoring Device: Medical device generating revenue through wearable hardware sales to healthcare systems and clinical facilities for continuous potassium monitoring in at-risk patients

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Proton Intelligence product offering

Product offering

Core offering

Proton Intelligence is developing a Continuous Potassium Monitoring (CKM) Platform — a real-time, on-demand potassium monitoring wearable designed to help clinicians treat and manage patients with kidney disease and cardio-kidney-metabolic conditions. The device delivers continuous potassium level data to enable safer, more precise management of hyperkalemia and unlocks life-saving treatments that cannot currently be deployed when patients have dangerous K+ levels.

Product overview

Proton Intelligence offers a single unified product — the Continuous Potassium Monitoring (CKM) Platform — which is a real-time, on-demand potassium monitoring wearable device. This platform is designed to enable clinicians to safely and precisely treat and manage patients with hyperkalemia and chronic kidney disease, unlocking life-saving treatments that cannot be deployed when patients have dangerous potassium levels.

Differentiator

Problem solved

Functional benefit

Products and services

  • Continuous Potassium Monitoring (CKM) Platform A real-time, on-demand potassium monitoring wearable designed to help clinicians treat and manage patients with kidney disease, hyperkalemia, and cardio-kidney-metabolic conditions by providing continuous potassium level data.

Quantifiable outcome

  • 3.7M+ Americans affected by hyperkalemia represent the addressable market for potassium monitoring technology

Companies that use Proton Intelligence

Customer profile

Segments3 records

Ideal customer profiles1 record

Proton Intelligence technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Proton Intelligence partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • MedTech InnovatorcoreStrategic or Co-development Partner · 1 January 2023Member of MedTech Innovator's 2023 Accelerator program, providing mentorship, resources, and networking for early-stage medical technology companies developing innovative healthcare solutions.
  • IndieBio San Francisco Batch 12coreStrategic or Co-development Partner · 1 January 2022Selected for IndieBio's San Francisco Batch 12 accelerator program, a prominent life sciences accelerator providing funding and support for biotech and medtech startups. Featured in TechCrunch coverage of the cohort.
  • BoostVC Tribe 18minorStrategic or Co-development PartnerMember of BoostVC's Tribe 18 accelerator program, supporting early-stage companies in the healthcare and blockchain sectors.
  • Creative Destruction Lab Vancouver Health StreamminorStrategic or Co-development PartnerParticipant in Creative Destruction Lab's Vancouver Health Stream, an accelerator program focused on scalable, seed-stage ventures with high-impact potential in health technology.
  • e@UBC Hatch Venture Builder ProgramminorStrategic or Co-development PartnerParticipant in e@UBC's Hatch Venture Builder Program, supporting entrepreneurship at the University of British Columbia and providing resources for early-stage venture development.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Proton Intelligence competitors and assessment

Company assessment

Direct peers

  • Dexcom: Continuous glucose monitoring wearable leader. Directly comparable as a wearable continuous biomarker monitoring platform with recurring consumables revenue; serves as the most direct analogue for what Proton aims to build in potassium.
  • Abbott Diabetes Care (FreeStyle Libre): CGM platform competing with Dexcom. Comparable wearable continuous biomarker business model and enterprise/payer commercialization playbook relevant to a future CKM go-to-market.
  • RenalSense: Continuous urine output monitoring for critically ill and acute kidney injury patients. Closest direct functional analogue in renal continuous monitoring, addressing similar hospital workflows.

Broad incumbents

  • Medtronic Diabetes: Broader medtech incumbent with diabetes and cardiac monitoring franchises. Relevant as a potential strategic acquirer and as a benchmark for an integrated patient-monitoring commercial machine.
  • Outset Medical: Tablo hemodialysis system for kidney care. Comparable as a renal-care device company commercializing novel technology into nephrology workflows; relevant for sales-cycle and reimbursement lessons.
  • Siemens Healthineers (Blood Gas / RAPIDPoint): Major diagnostic instrument maker including blood-gas/electrolyte analyzers used in clinical potassium measurement. Relevant as a benchmark for incumbent diagnostic adoption and a potential strategic acquirer.

Emerging players

  • Nova Biomedical: Manufacturer of electrolyte and blood-gas analyzers (including potassium measurement). Comparable as a potassium-measurement technology competitor in clinical settings, though primarily bench-top rather than wearable.
  • Quanta Dialysis Technologies: Compact hemodialysis system developer. Comparable as a venture-backed medtech commercializing innovative renal-care technology into clinical workflows with similar reimbursement and adoption dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights5 records

Customer concentration

Proton Intelligence social profiles

Digital presence

Proton Intelligence financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Proton Intelligence leadership team

Management profile

Number of profiles

Profiles2 records

Proton Intelligence funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Proton Intelligence M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Proton Intelligence

What does Proton Intelligence do?

Proton Intelligence is developing a Continuous Potassium Monitoring (CKM) Platform — a real-time, on-demand potassium monitoring wearable designed to help clinicians treat and manage patients with kidney disease and cardio-kidney-metabolic conditions. The device delivers continuous potassium level data to enable safer, more precise management of hyperkalemia and unlocks life-saving treatments that cannot currently be deployed when patients have dangerous K+ levels.

Is Proton Intelligence a public or private company?

Proton Intelligence is a private company. It is classified as venture growth investor backed and is currently operating.

When was Proton Intelligence founded?

Proton Intelligence was founded in 2020. It employs 11 to 50 people.

Where is Proton Intelligence based?

Proton Intelligence is headquartered in Vancouver, Canada, in the North America region.

How does Proton Intelligence make money?

One revenue line is on record: continuous Potassium Monitoring Device.

Who are Proton Intelligence's main competitors?

Direct peers on record are Dexcom, Abbott Diabetes Care (FreeStyle Libre) and RenalSense. Broad incumbents are Medtronic Diabetes, Outset Medical and Siemens Healthineers (Blood Gas / RAPIDPoint). Emerging players are Nova Biomedical and Quanta Dialysis Technologies.

Does Proton Intelligence have an API?

No public API is recorded for Proton Intelligence.

What industry is Proton Intelligence in?

Proton Intelligence's product category is Continuous Potassium Monitoring Wearables. Its primary akta.pro industry code is HLAHAKAJ, Renal Diagnostics & Monitoring (eGFR/Creatinine POC, Urine Analyzers, BP/Fluid Status), with a secondary code of HLAHAKAK, Renal Care Ancillaries (Anemia Management Devices, Phosphate Binder Support, Nutrition Monitoring). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WebcapitalriesgoWe Venture Capital invierte en las medtech Oxford Cancer Analytics y Proton IntelligenceWe Venture Capital invested in Oxford Cancer Analytics and Proton Intelligence, with the two startups raising about $17 million. We VC led an $11 million Series A in OXcan and a $6.95 million Seed in Proton Intelligence. Both companies aim to improve cancer and kidney disease screening.Pulse 2.0Proton Intelligence: Continuous Potassium Monitoring Company Raises $6.95 Million (Seed)Proton Intelligence raised $6.95 million in seed funding from SOSV, We Venture Capital, and others. The company's Continuous Potassium Monitoring platform aims to provide remote potassium levels for patients with kidney disease or heart failure, addressing a gap that leads to nearly 40% higher 6-month mortality. Clinical studies are underway, with a pivotal study planned for 2026.NextUnicornProton Intelligence Raises $6.95M to Launch Potassium Monitoring Tech – Next UnicornProton Intelligence, a Canada-based startup, raised $6.95 million in seed funding led by SOSV to develop a continuous potassium monitoring device for chronic kidney disease and heart failure risk. The device connects to a smartphone app and is planned for launch in 2025, with clinical trials underway.Financial PostContinuous Biomarker Monitoring Pioneer Proton Intelligence Inc Announces a $6.95 Million Seed Raise to Initiate Human Trials for Potassium Monitoring in Patients With Kidney DiseaseProton Intelligence Inc. closed a $6.95 million seed round to initiate human trials for its continuous potassium monitoring platform. The company aims to address dangerous potassium fluctuations in kidney disease and heart failure, which can lead to cardiac arrhythmias and sudden death.TechCrunchProton’s device aims to help those with kidney disease and cut heart-failure risksProton Intelligence, a Canada-based startup, closed a $6.95 million seed round led by SOSV to develop a continuous potassium monitoring device. The device, due to launch in 2025, will be inserted under the skin and connect to a smartphone app, with clinical trials underway.Business Wire BlogContinuous Biomarker Monitoring Pioneer Proton Intelligence Inc Announces a $6.95 Million Seed Raise to Initiate Human Trials for Potassium Monitoring in Patients With Kidney DiseaseProton Intelligence Inc. closed a $6.95 million seed round led by SOSV, We Venture Capital, and others to fund human trials of its continuous potassium monitoring platform. The company aims to address dangerous potassium fluctuations in kidney disease and heart failure, with a pivotal study planned for 2026.Business Wire BlogContinuous Biomarker Monitoring Pioneer Proton Intelligence Inc Announces a $6.95 Million Seed Raise to Initiate Human Trials for Potassium Monitoring in Patients With Kidney DiseaseProton Intelligence Inc. closed a $6.95 million seed round to fund human trials of its continuous potassium monitoring platform for kidney disease patients. The company plans a pivotal study in 2026, with clinical studies already underway in end-stage renal disease and chronic kidney disease populations.IndiebioProtonIntel: The First Ever Continuous K+ MonitoringProton Intelligence, led by CEO Sahan Ranamukha and COO Francis Steiner, has developed the world's first continuous wearable potassium monitoring platform, achieving selectivity and biocompatibility specifications during its participation in the IndieBio accelerator program. The company plans to initiate pilot programs with major dialysis providers and nephrology practices to validate the device's ability to improve value-based kidney care and reduce hospitalizations. Preliminary testing indicates the sensor can detect transient potassium increases following dietary intake, validating its potential as a critical tool for managing chronic kidney disease patients.